Key Points
- Insider sale: Director Janet Jill Hopkins sold 17,109 shares on Nov. 17 at an average price of $5.42 for about $92,731, reducing her stake by 6.34% to 252,685 shares (≈$1.37M).
- Heavy institutional ownership: Institutional investors own 96.75% of AURA, with recent sizable positions added or increased by Frazier Life Sciences (~$31.9M new stake), Long Focus Capital, Vanguard and others.
- Market and analyst context: AURA trades near $5.50 (1-year range $4.34–$9.78) with a market cap of ≈$349M and negative P/E; analysts have an average rating of “Moderate Buy” and an average target of $20.50.
Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Janet Jill Hopkins sold 17,109 shares of Aura Biosciences stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $5.42, for a total value of $92,730.78. Following the completion of the sale, the insider owned 252,685 shares of the company's stock, valued at approximately $1,369,552.70. The trade was a 6.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Aura Biosciences Trading Down 0.5%
Shares of NASDAQ:AURA opened at $5.50 on Tuesday. Aura Biosciences, Inc. has a 1-year low of $4.34 and a 1-year high of $9.78. The stock has a market capitalization of $349.25 million, a P/E ratio of -2.84 and a beta of 0.45. The business has a 50-day moving average price of $5.99 and a two-hundred day moving average price of $6.23.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.06. As a group, equities analysts predict that Aura Biosciences, Inc. will post -1.66 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in AURA. Frazier Life Sciences Management L.P. acquired a new stake in Aura Biosciences in the 2nd quarter valued at $31,926,000. Long Focus Capital Management LLC boosted its stake in shares of Aura Biosciences by 30.8% during the 1st quarter. Long Focus Capital Management LLC now owns 3,319,582 shares of the company's stock worth $19,453,000 after buying an additional 781,808 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Aura Biosciences by 16.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,890,503 shares of the company's stock valued at $17,863,000 after acquiring an additional 413,001 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Aura Biosciences by 5.9% in the second quarter. Franklin Resources Inc. now owns 2,340,810 shares of the company's stock valued at $14,653,000 after acquiring an additional 130,221 shares during the last quarter. Finally, Nantahala Capital Management LLC raised its holdings in Aura Biosciences by 67.1% during the second quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company's stock worth $13,257,000 after acquiring an additional 850,000 shares in the last quarter. Institutional investors own 96.75% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts have commented on AURA shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aura Biosciences in a research report on Tuesday, November 11th. HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of Aura Biosciences in a research report on Wednesday, August 13th. Finally, Zacks Research raised Aura Biosciences from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Aura Biosciences presently has an average rating of "Moderate Buy" and an average target price of $20.50.
Get Our Latest Analysis on Aura Biosciences
Aura Biosciences Company Profile
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
